Credit: Alvogen, Inc. Fentanyl is an opioid agonist indicated for the management of severe or persistent pain in opioid-tolerant patients. At this time, Alvogen Inc has received 1 serious adverse ...
MIRAMAR, Fla., Feb. 17, 2025 /PRNewswire/ -- Aveva Drug Delivery systems (A DifGen company), a leader in transdermal drug delivery systems based out of Miramar - Florida is proud to announce the ...
The U.S. Food and Drug Administration announced last week that a pharmaceutical company is removing a fentanyl patch from ...
MORRISTOWN, N.J., Jan. 31, 2025 /PRNewswire/ -- Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the ...
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl ...
NDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials needed prior to submission. AVERSA™ Fentanyl incorporates Nutriband's Aversa™ ...
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it ...
Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing Nutriband working to complete the commercial scale-up prior to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results